The IDH-1 inhibitor ivosidenib is currently FDA- and EMA-approved for patients with relapsed/refractory AML or chemotherapy-ineligible patients with AML with sensitizing IDH-1 mutations. The gene discussed is IDH1; the disease is acute myeloid leukemia.